An Evolving Paradigm in Borderline Resectable and Locally Advanced Pancreatic Cancer: Current Strategies and Opportunities for the Future
DOI:
https://doi.org/10.58931/cot.2024.1224Abstract
Pancreatic ductal adenocarcinoma (PDAC), a cancer of the gastrointestinal tract, has been increasing in incidence, with an estimated doubling worldwide over the past two decades. Despite increases in awareness and innovations in genomics and drug discovery, 5-year survival remains low, at only 10%. This is in part owing to the majority of patients being diagnosed at the advanced stage of the disease, in addition to chemotherapy recalcitrant disease.
Surgical resection is necessary for a potential cure, however, this is only possible for the 10% of patients who present with resectable disease and potentially for those with borderline resectable disease. Locally advanced pancreatic cancer accounts for approximately 30% of those with PDAC and most of those patients are often precluded from curative intent surgery due to major vascular invasion and local infiltration into peri-pancreatic soft tissue. In cases of locally advanced disease, induction chemotherapy is often used, identifying the subgroup of patients more suited for local treatments and those who may later develop metastases. The treatment regimens used for patients with locally advanced PDAC are often extrapolated from trials involving patients with metastatic disease. In some cases, responses to neoadjuvant therapy have allowed for surgical resection, albeit these aggressive resections were associated with significant morbidity.
There is growing interest in identifying the optimal neoadjuvant treatment for patients with borderline resectable pancreatic cancer (BRPC) and locally advanced PDAC (LAPC) in an effort to improve outcomes. Here we review therapeutic strategies for borderline resectable and locally advanced PDAC, with a focus on novel systemic therapy regimens, chemoradiation, and different radiation modalities.
References
Klein AP. Pancreatic cancer: a growing burden. Lancet Gastroenterol Hepatol. 2019;4(12):895-896. doi:10.1016/S2468-1253(19)30323-1 DOI: https://doi.org/10.1016/S2468-1253(19)30323-1
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493-502. doi:10.1038/s41575-021-00457-x DOI: https://doi.org/10.1038/s41575-021-00457-x
Millikan K, Deziel D, Silverstein J, Kanjo TM, Christein JD, Doolas A, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. JAMA. 1999;65(7):623-624. http://dx.doi.org/10.1016/j.jaci.2012.05.050 DOI: https://doi.org/10.1177/000313489906500704
Loveday BPT, Zilbert N, Serrano PE, Tomiyama K, Tremblay A, Fox AM, et al. Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas. HPB (Oxford). 2019;21(6):643-652. doi:10.1016/j.hpb.2018.10.004 DOI: https://doi.org/10.1016/j.hpb.2018.10.004
Khachfe HH, Habib JR, Nassour I, Al Harthi S, Jamali FR. Borderline resectable and locally advanced pancreatic cancers: A review of definitions, diagnostics, strategies for treatment, and future directions. Pancreas. 2021;50(9):1243-1249. doi:10.1097/MPA.0000000000001924 DOI: https://doi.org/10.1097/MPA.0000000000001924
Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E. Resectable, borderline, and locally advanced pancreatic cancer—“the good, the bad, and the ugly” candidates for surgery? J Gastrointest Oncol. 2021;12(5):2450-2460. doi:10.21037/jgo-2020-slapc-04 DOI: https://doi.org/10.21037/jgo-2020-slapc-04
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008-2020. doi:10.1016/S0140-6736(20)30974-0 DOI: https://doi.org/10.1016/S0140-6736(20)30974-0
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (Pancreatic Adenocarcinoma). Pancreatic Cancer (Version 1.2024). Accessed February 25, 2024. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
Versteijne E, Van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC Trial. J Clin Oncol. 2022;40(11):1220-1230. doi:10.1200/JCO.21.02233 DOI: https://doi.org/10.1200/JCO.21.02233
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157-168. doi:10.1016/S2468-1253(22)00348-X DOI: https://doi.org/10.1016/S2468-1253(22)00348-X
Koerkamp BG, Jannsen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, et al. Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial. Ann Oncol. 2023;34(Supplement 2):1281-1282. DOI: https://doi.org/10.1016/j.annonc.2023.10.084
Yamaguchi J, Yokoyama Y, Fujii T, Suguru Y, Takami H, Kawashima H, et al. Results of a phase ii study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg. 2022;275(6):1043-1049. doi:10.1097/SLA.0000000000005430 DOI: https://doi.org/10.1097/SLA.0000000000005430
Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49(2):190-194. doi:10.1093/jjco/hyy190 DOI: https://doi.org/10.1093/jjco/hyy190
Unno M, Motoi F, Matsuyama Y, Satoi S, Matsumoto I, Aosasa S, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-15). Journal of Clinical Oncology. 2019;37, Number 4_suppl. doi: 10.1200/JCO.2019.37.4_suppl.18 DOI: https://doi.org/10.1200/JCO.2019.37.4_suppl.189
Kondo N, Uemura K, Sudo T, Hashhimoto Y, Sumiyoshi T, Okada K, et al. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. Eur J Cancer. 2021;159:215-223. doi:10.1016/j.ejca.2021.10.012 DOI: https://doi.org/10.1016/j.ejca.2021.10.012
Takahashi S, Ohno I, Ikeda M, Konishi M, Kobayashi T, Akimoto T, et al. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: a phase II open-label multicenter prospective trial (JASPAC05). Ann Surg. 2022;276(5):E510-E517. doi:10.1097/SLA.0000000000004535 DOI: https://doi.org/10.1097/SLA.0000000000004535
Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek L, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963-969. doi:10.1001/jamaoncol.2018.0329 DOI: https://doi.org/10.1001/jamaoncol.2018.0329
Jang JY, Han Y, Lee H, Kim S-W, Kwon W, Lee K-H,et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215-222. doi:10.1097/SLA.0000000000002705 DOI: https://doi.org/10.1097/SLA.0000000000002705
Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX Plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263-1270. doi:10.1001/jamaoncol.2022.2319 DOI: https://doi.org/10.1001/jamaoncol.2022.2319
Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol (Madr). 2015;54(7):979-985. doi:10.3109/0284186X.2015.1004367 DOI: https://doi.org/10.3109/0284186X.2015.1004367
Chuong MD, Springett GM, Freilich JM, Park CK, WEber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516-522. doi:10.1016/j.ijrobp.2013.02.022 DOI: https://doi.org/10.1016/j.ijrobp.2013.02.022
Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135-144. doi:10.1016/j.ejca.2022.12.014 DOI: https://doi.org/10.1016/j.ejca.2022.12.014
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801-810. doi:10.1016/S1470-2045(16)00172-8 DOI: https://doi.org/10.1016/S1470-2045(16)00172-8
Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(2):128-138. DOI: https://doi.org/10.1016/S2468-1253(20)30330-7
Arscott WT, Nead KT, Bear A, Venigalla S, Shabason J, Lukens JN, et al. Concurrent Nab-paclitaxel and radiotherapy: novel radiosensitization for borderline resectable or unresectable pancreatic cancer. Am J Clin Oncol. 2021;44(9):469-474. doi:10.1097/COC.0000000000000854 DOI: https://doi.org/10.1097/COC.0000000000000854
Su YY, Chiu YF, Li CP, Yang SH, Lin J, Lin SJ, et al. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. Br J Cancer. 2022;126(7):1018-1026. doi:10.1038/s41416-021-01649-7 DOI: https://doi.org/10.1038/s41416-021-01649-7
Lacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806-1813. doi:10.1200/JCO.2008.17.7188 DOI: https://doi.org/10.1200/JCO.2008.17.7188
Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artu P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844-1853. doi:10.1001/jama.2016.4324 DOI: https://doi.org/10.1001/jama.2016.4324
Fietkau R, Grützmann R, Wittel UA, Croner RS, Jacobasch, L, Neumann UP, et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial. Strahlentherapie Onkol. 2021;197(1):8-18. doi:10.1007/s00066-020-01680-2 DOI: https://doi.org/10.1007/s00066-020-01680-2
Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiroaka N, et al. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol. 2021;51(2):235-243. doi:10.1093/jjco/hyaa198 DOI: https://doi.org/10.1093/jjco/hyaa198
Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58(4):1017-1021. doi:10.1016/j.ijrobp.2003.11.004 DOI: https://doi.org/10.1016/j.ijrobp.2003.11.004
Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63(2):320-323. doi:10.1016/j.ijrobp.2005.07.002 DOI: https://doi.org/10.1016/j.ijrobp.2005.07.002
Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72(3):678-686. doi:10.1016/j.ijrobp.2008.01.051 DOI: https://doi.org/10.1016/j.ijrobp.2008.01.051
Rudra S, Jiang N, Rosenberg SA, Olson JR, Roach MC, Wan L, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019;8(5):2123-2132. doi:10.1002/cam4.2100 DOI: https://doi.org/10.1002/cam4.2100
Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das, P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755-765. doi:10.1016/j.ijrobp.2015.12.003 DOI: https://doi.org/10.1016/j.ijrobp.2015.12.003
Reyngold M, O’Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, Romesser RB, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7(5):735-738. doi:10.1001/jamaoncol.2021.0057 DOI: https://doi.org/10.1001/jamaoncol.2021.0057
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang, N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144-150. doi:10.1038/s41586-023-06063-y DOI: https://doi.org/10.1038/s41586-023-06063-y
van ’t Land FR, Latifi D, Moskie M, Homs MYV, Bosscha K, Bonsing BA, et al. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFI. Radiother Oncol. 2023;183:109541. doi:10.1016/j.radonc.2023.109541 DOI: https://doi.org/10.1016/j.radonc.2023.109541
Hewitt DB, Nissen N, Hatoum H, et al. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-l (HyperAcute-Pancreas) immunotherapy in subjectswith borderline resectable or locally advanced unresectable pancreatic cancer. Ann Surg. 2022;275(1):45-53. doi:10.1097/SLA.0000000000004669 DOI: https://doi.org/10.1097/SLA.0000000000004669
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Oncology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
